Two separate brain pathways — additive effects
Primary target
Hypothalamus (arcuate nucleus)
Also affects
Mesolimbic reward circuit, vagus nerve
Primary target
Area postrema (brainstem)
Also affects
Ventral tegmental area, medial prefrontal cortex
Different receptors, different brain regions → effects add up, not cancel out
What amylin is
Amylin (also called IAPP, or islet amyloid polypeptide) is a hormone released with insulin by the beta cells of the pancreas. It comes at mealtimes. Its main job is to signal fullness and slow the speed at which food leaves the stomach.
People with type 2 diabetes release less amylin as well as less insulin. That partly explains why their sense of fullness often does not work as it should.
How amylin suppresses appetite
Amylin works via distinct brain regions and pathways to GLP-1:
Area postrema access
Amylin acts on the area postrema in the brainstem. That region has no blood-brain barrier, so hormones in the blood can reach it directly. The signal is then passed on to the lateral hypothalamus, which suppresses appetite.
Reward circuit suppression
Amylin acts on two other brain areas, the ventral tegmental area and the medial prefrontal cortex. That suppresses impulsive food-seeking and makes food less rewarding.
Gastric slowing
Like GLP-1, amylin slows how fast the stomach empties. Food stays there longer, so the feeling of fullness lasts.
Glucagon suppression
Amylin holds back glucagon release after meals, which helps control blood sugar.
Why combining with GLP-1 matters
Plain English:
Amylin is a separate fullness signal. The pancreas releases it at mealtimes, and it tells the brain you've eaten enough through different nerve pathways to GLP-1. Combining amylin signals with GLP-1 signals appears to add to weight loss. Each signal reinforces the other from a different angle in the brain.
GLP-1 and amylin act on different receptors in different brain regions. Their effects do not overlap much. They work alongside each other. In Phase 3 trials, CagriSema (cagrilintide + semaglutide) produced 20.4% mean weight loss. That is notably greater than semaglutide alone (~15%) in comparable populations.
Pipeline status
Neither CagriSema nor Amycretin is currently approved. CagriSema has had an NDA filed with the FDA (December 2025) and is under review. An NDA is a New Drug Application, the formal request for approval. Amycretin is in earlier development (Phase 3 planned). These drugs are not available for prescription.
Common questions
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: